Skip to main content
Have a personal or library account? Click to login
Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk Cover

Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk

Archives of Industrial Hygiene and Toxicology
Volume 60 (2009): Issue 2 (June 2009)
By: ,   and    
Open Access
|Jul 2009
References

References

  1. Meyer U. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997;37:269--96.10.1146/annurev.pharmtox.37.1.2699131254
    Search in Google Scholar
  2. Linder MW, Prough RA, Valdes R. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem 1997;43:254--66.10.1093/clinchem/43.2.254
    Search in Google Scholar
  3. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348:529--37.10.1056/NEJMra02002112571261
    Search in Google Scholar
  4. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004;429:464--8.10.1038/nature0262615164072
    Search in Google Scholar
  5. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001;41:101--21.10.1146/annurev.pharmtox.41.1.10111264452
    Search in Google Scholar
  6. Omenn GS. Prospects for pharmacogenetics and ecogenetics in the new millennium. Drug Metab Dispos 2001;29:611--4.
    Search in Google Scholar
  7. Reszka E, Wasowicz W, Gromadzinska J. Genetic polymorphism of xenobiotic metabolising enzymes, diet and cancer susceptibility. Br J Nutr 2006;96:609--19.
    Search in Google Scholar
  8. Schmidt CW. Toxicogenomics - An emergin discipline. Eniron Health Perspect 2002;110:A750--5.10.1289/ehp.110-a248124085112003768
    Search in Google Scholar
  9. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn-Schmiedeberg's Arch Pharmacol 2004;369:89--104.10.1007/s00210-003-0819-z14574440
    Search in Google Scholar
  10. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, Kliewer SA. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 2002;62:638--46.10.1124/mol.62.3.63812181440
    Search in Google Scholar
  11. Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 2005;28:249--68.10.1007/BF0297778915832810
    Search in Google Scholar
  12. Belitsky GA, Yakubovskaya MG. Genetic polymorphism and variability of chemical carcinogenesis. Biochemistry (Moscow) 2008;73:543--54.10.1134/S0006297908050076
    Search in Google Scholar
  13. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP, Sutter TR. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 1996;56:2979--84.
    Search in Google Scholar
  14. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006;25:1679--91.10.1038/sj.onc.1209377
    Search in Google Scholar
  15. Autrup H. Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response. Mutat Res 2000;464:65--76.10.1016/S1383-5718(99)00167-9
    Search in Google Scholar
  16. Zhou M, Maitra SR, Wang P. The potential role of transcription factor aryl hydrocarbon receptor in downregulation of hepatic cytochrome P-450 during sepsis. Int J Mol Med 2008;21:423--8.10.3892/ijmm.21.4.423
    Search in Google Scholar
  17. Yang X, Solomon S, Fraser LR, Trombino AF, Liu D, Sonenshein GE, Hestermann EV, Sherr DH. Constitutive regulation of CYP1B1 by the aryl hydrocarbon receptor (AhR) in pre-malignant and malignant mammary tissue. J Cell Biochem 2008;104:402--17.10.1002/jcb.2163018059014
    Search in Google Scholar
  18. Oinonen T Lindros KO. Zonation of hepatic cytochrome P-450 expression and regulation. Biochem J 1998;329:17--35.10.1042/bj329001712190099405271
    Search in Google Scholar
  19. Lamba JK. Pharmacogenetics of the constitutive androstane receptor. Pharmacogenomics 2008;9:71--83.10.2217/14622416.9.1.7118154449
    Search in Google Scholar
  20. Chen D, Tian T, Wang H, Liu H, Hu Z, Wang Y, Liu Y, Ma H, Fan W, Miao R, Sun W, Wang Y, Qian J, Jin L, Wei Q, Shen H, Huang W, Lu D. Association of human aryl hydrocarbon receptor gene polymorphisms with risk of lung cancer among cigarette smokers in a Chinese population. Pharmacogenet Genomics 2009;19:25--34.10.1097/FPC.0b013e328316d8d818818557
    Search in Google Scholar
  21. Houston JB, Galetin A. Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr Drug Metab 2008;9:940--51.10.2174/13892000878648516418991591
    Search in Google Scholar
  22. Hyland R, Dickins M, Collins C, Jones H, Jones B. Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmacol 2008;66:498--507.10.1111/j.1365-2125.2008.03198.x256110118647303
    Search in Google Scholar
  23. Youdim KA, Zayed A, Dickins M, Phipps A, Griffiths M, Darekar A, Hyland R, Fahmi O, Hurst S, Plowchalk DR, Cook J, Guo F, Obach RS. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. Br J Clin Pharmacol 2008;65:680--92.10.1111/j.1365-2125.2007.03070.x243247818279465
    Search in Google Scholar
  24. Diaz DS, Kozar MP, Smith KS, Asher CO, Sousa JC, Schiehser GA, Jacobus DP, Milhous WK, Skillman DR, Shearer TW. Role of specific cytochrome P450 isoforms in the conversion of phenoxypropoxybiguanide analogs in human liver microsomes to potent antimalarial dihydrotriazines. Drug Metab Dispos 2008;36:380--5.10.1124/dmd.106.01392018006651
    Search in Google Scholar
  25. Lobo ED, Bergstrom RF, Reddy S, Quinlan T, Chappell J, Hong Q, Ring B, Knadler MP. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet 2008;47:191--202.10.2165/00003088-200847030-0000518307373
    Search in Google Scholar
  26. Andersson TB, Sjoberg H, Hoffmann KJ, Boobis AR, Watts P, Edwards RJ, Lake BG, Price RJ, Renwick AB, Gomez-Lechon MJ, Castell JV, Ingelman-Sundberg M, Hidestrand M, Goldfarb PS, Lewis DF, Corcos L, Guillouzo A, Taavitsainen P, Pelkonen O. An assesment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant. Drug Metab Dispos 2001;7:12--20.
    Search in Google Scholar
  27. Ulbricht C, Chao W, Costa D, Rusie-Seamon E, Weissner W, Woods J. Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration. Curr Drug Metab 2008;9:1062--119.10.2174/13892000878692778519075623
    Search in Google Scholar
  28. Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci 2006;78:2131--45.10.1016/j.lfs.2005.12.01016442130
    Search in Google Scholar
  29. Pittler MH, Ernst E. Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment Pharmacol Ther 2003;18:451--71.10.1046/j.1365-2036.2003.01689.x12950418
    Search in Google Scholar
  30. Nebert DW, Ingelman-Sundberg M, Daly AK. Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. Drug Metabol Rev 1999;31:467--87.10.1081/DMR-100101931
    Search in Google Scholar
  31. Nelson D. Cytochrome P450 Homepage http://drnelson.utmem.edu/CytochromeP450
    Search in Google Scholar
  32. Bosch TM, Meijerman I, Beijnen JH, Schellens JH. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 2006;45:253--85.10.2165/00003088-200645030-0000316509759
    Search in Google Scholar
  33. Petsalo A, Turpeinen M, Pelkonen O, Tolonen A. Analysis of nine drugs and their cytochrome P450-specific probe metabolites from urine by liquid chromatography-tandem mass spectrometry utilizing sub 2μm particle size column. J Chromatogr A 2008;1215:107--15.10.1016/j.chroma.2008.10.12219019380
    Search in Google Scholar
  34. de Leon J, Susce MT, Johnson M, Hardin M, Maw L, Shao A, Allen AC, Chiafari FA, Hillman G, Nikoloff DM. DNA Microarray Technology in the Clinical Environment: The AmpliChip CYP450 Test for CYP2D6 and CYP2C19 Genotyping. CNS Spectr 2009;14:19--34.10.1017/S109285290002002219169185
    Search in Google Scholar
  35. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200--5.10.1001/jama.279.15.12009555760
    Search in Google Scholar
  36. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001;250:186--200.10.1046/j.1365-2796.2001.00879.x11555122
    Search in Google Scholar
  37. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001;286:2270--9.10.1001/jama.286.18.227011710893
    Search in Google Scholar
  38. Shimada T, Gillam EM, Sutter TR, Strickland PT, Guengerich FP, Yamazaki H. Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos 1997;25:617--22.
    Search in Google Scholar
  39. Fujii-Kuriyama Y, Ema M, Mimura J, Matsushita N, Sogawa K. Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene. Pharmacogenetics 1995;5:149--53.10.1097/00008571-199512001-000187581486
    Search in Google Scholar
  40. Nebert DW, McKinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 1996;15:273--80.10.1089/dna.1996.15.2738639263
    Search in Google Scholar
  41. Ingelman-Sundberg M, Daly AK, Nebert DW. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. http://www.cypalleles.ki.se/
    Search in Google Scholar
  42. Inoue K, Asao T, Shimada T. Ethnic-related differences in the frequency distribution of genetic polymorphisms in the CYP1A1 and CYP1B1 genes in Japanese and Caucasian populations. Xenobiotica 2000;30:285--95.10.1080/00498250023767710752643
    Search in Google Scholar
  43. Zhu K, Hunter S, Payne-Wilks K, Sutcliffe C, Bentley C, Roland CL, Williams SM. Potential differences in breast cancer risk factors based on CYP1A1 MspI and African-American-specific genotypes. Ethn Dis 2006;16:207--15.
    Search in Google Scholar
  44. Taioli E, Crofts F, Trachman J, Demopoulos R, Toniolo P, Garte SJ. A specific African-American CYP1A1 polymorphism is associated with adenocarcinoma of the lung. Cancer Res 1995;55:472--3.
    Search in Google Scholar
  45. Kiyohara C, Yoshimasu K, Shirakawa T, Hopkin JM. Genetic polymorphisms and environmental risk of lung cancer: a review. Rev Environ Health 2004;19:15--38.10.1515/REVEH.2004.19.1.1515186038
    Search in Google Scholar
  46. Little J, Sharp L, Masson LF, Brockton NT, Cotton SC, Haites NE, Cassidy J. Colorectal cancer and genetic polymorphisms of CYP1A1, GSTM1 and GSTT1: a case-control study in the Grampian region of Scotland. Int J Cancer 2006;119:2155--64.10.1002/ijc.2209316823842
    Search in Google Scholar
  47. Nakachi K, Imai K, Hayashi S-I, Kawajiri K. Polymorphism of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 1993;53:2994--9.
    Search in Google Scholar
  48. Kihara M, Kihara M, Noda K. Risk of smoking for squamos and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population. Carcinogenesis 1995;16:2331--6.10.1093/carcin/16.10.23317586131
    Search in Google Scholar
  49. Moretti M, Dell'Omo M, Villarini M, Pastorelli R, Muzi G, Airoldi L, Pasquini R. Primary DNA damage and genetic polymorphisms for CYP1A1, EPHX and GSTM1 in workers at a graphite electrode manufacturing plant. BMC Public Health 2007;7:270.10.1186/1471-2458-7-270208203517908297
    Search in Google Scholar
  50. Shah PP, Singh AP, Singh M, Mathur N, Pant MC, Mishra BN, Parmar D. Interaction of cytochrome P4501A1 genotypes with other risk factors and susceptibility to lung cancer. Mutat Res 2008;639:1--10.10.1016/j.mrfmmm.2007.10.00618082227
    Search in Google Scholar
  51. Vineis P, Anttila S, Benhamou S, Spinola M, Hirvonen A, Kiyohara C, Garte SJ, Puntoni R, Rannug A, Strange RC, Taioli E. Evidence of gene-gene interactions in lung carcinogenesis in a large pooled analysis. Carcinogenesis 2007;28:1902--5.10.1093/carcin/bgm03917307802
    Search in Google Scholar
  52. Cote ML, Wenzlaff AS, Bock CH, Land SJ, Santer SK, Schwartz DR, Schwartz AG. Combinations of cytochrome P-450 genotypes and risk of early-onset lung cancer in Caucasians and African Americans: a population-based study. Lung Cancer 2007;55:255--62.10.1016/j.lungcan.2006.11.002183988517174438
    Search in Google Scholar
  53. Cote ML, Yoo W, Wenzlaff AS, Prysak GM, Santer S, Claeys GB, Vandyke AL, Land SJ, Schwartz AG. Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women. Carcinogenesis 2009;30:626--35.10.1093/carcin/bgp033266445519174490
    Search in Google Scholar
  54. Shi X, Zhou S, Wang Z, Zhou Z, Wang Z. CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis. Lung Cancer 2008;59:155--63.10.1016/j.lungcan.2007.08.00417900751
    Search in Google Scholar
  55. Kumar M, Agarwal SK, Goel SK. Lung cancer risk in north Indian population: role of genetic polymorphisms and smoking. Mol Cell Biochem 2009;322:73--9.10.1007/s11010-008-9941-z19009239
    Search in Google Scholar
  56. Yoon KA, Kim JH, Gil HJ, Hwang H, Hwangbo B, Lee JS. CYP1B1, CYP1A1, MPO, and GSTP1 polymorphisms and lung cancer risk in never-smoking Korean women. Lung Cancer 2008;60:40--6.10.1016/j.lungcan.2007.09.00917980933
    Search in Google Scholar
  57. Miyoshi Y, Takahashi Y, Egawa C, Noguchi S. Breast cancer risk associated with CYP1A1 genetic polymorphisms in Japanese women. Breast J 2002;8:209--15.10.1046/j.1524-4741.2002.08404.x12100112
    Search in Google Scholar
  58. Miyoshi Y, Ando A, Hasegawa S, Ishitobi M, Yamamura J, Irahara N, Tanji Y, Taguchi T, Tamaki Y, Noguchi S. Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk. Eur J Cancer 2003;39:2531--7.10.1016/j.ejca.2003.08.01714602139
    Search in Google Scholar
  59. Li Y, Millikan RC, Bell DA, Cui L, Tse Ch-KJ, Newman B, Conway K. Polychlorinated biphenyls, cytochrome P450 1A1 (CYP1A1) polymorphisms, and breast cancer risk among African American women and white women in North Carolina: a population-based case-control study. Breast Cancer Res 2005;7:12--8.10.1186/bcr941106409515642161
    Search in Google Scholar
  60. Gulyaeva LF, Mikhailova ON, PustyInyak VO, Kim IV 4th, Gerasimov AV, Krasilnikov SE, Filipenko ML, Pechkovsky EV. Comparative analysis of SNP in estrogen-metabolizing enzymes for ovarian, endometrial, and breast cancers in Novosibirsk, Russia. Adv Exp Med Bio 2008;617:359--66.10.1007/978-0-387-69080-3_3418497059
    Search in Google Scholar
  61. Hirata H, Hinoda Y, Okayama N, Suehiro Y, Kawamoto K, Kikuno N, Rabban JT, Chen LM, Dahiya R. CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer 2008;112:1964--73.10.1002/cncr.2339218318428
    Search in Google Scholar
  62. Li R, Shugart YY, Zhou W, An Y, Yang Y, Zhou Y, Zhang B, Lu D, Wang H, Qian J, Jin L. Common genetic variations of the cytochrome P450 1A1 gene and risk of hepatocellular carcinoma in a Chinese population. Eur J Cancer 2009;45:1239--47.10.1016/j.ejca.2008.11.00719110417
    Search in Google Scholar
  63. Yuan X, Zhou G, Zhai Y, Xie W, Cui Y, Cao J, Zhi L, Zhang H, Yang H, Zhang X, Qiu W, Peng Y, Zhang X, Yu L, Xia X, He F. Lack of association between the functional polymorphisms in the estrogen-metabolizing genes and risk for hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2008;17:3621--7.10.1158/1055-9965.EPI-08-074219064581
    Search in Google Scholar
  64. Park SK, Andreotti G, Sakoda LC, Gao YT, Rashid A, Chen J, Chen BE, Rosenberg PS, Shen MC, Wang BS, Han TQ, Zhang BH, Yeager M, Chanock S, Hsing AW. Variants in Hormone-Related Genes and the Risk of Biliary Tract Cancers and Stones: A Population-based Study in China. Carcinogenesis 2009;30:606--14.10.1093/carcin/bgp024266445319168589
    Search in Google Scholar
  65. Pereira Serafim PV, Cotrim Guerreiro da Silva ID, Manoukias Forones N. Relationship between genetic polymorphism of CYP1A1 at codon 462 (Ile462Val) in colorectal cancer. Int J Biol Markers 2008;23:18--23.10.5301/JBM.2008.4373
    Search in Google Scholar
  66. Goode EL, Potter JD, Bamlet WR, Rider DN, Bigler J. Inherited variation in carcinogen-metabolizing enzymes and risk of colorectal polyps. Carcinogenesis 2007;28:328--41.10.1093/carcin/bgl13516926176
    Search in Google Scholar
  67. Hou L, Chatterjee N, Huang WY, Baccarelli A, Yadavalli S, Yeager M, Bresalier RS, Chanock SJ, Caporaso NE, Ji BT, Weissfeld JL, Hayes RB. CYP1A1 Val462 and NQO1 Ser187 polymorphisms, cigarette use, and risk for colorectal adenoma. Carcinogenesis 2005;26:1122--8.10.1093/carcin/bgi05415731166
    Search in Google Scholar
  68. Nagata K, Yamazoe Y. Genetic polymorphism of human cytochrome p450 involved in drug metabolism. Drug Metab Pharmacokinet 2002;17:167--89.10.2133/dmpk.17.16715618668
    Search in Google Scholar
  69. Allorge D, Chevalier D, Lo-Guidice JM, Cauffiez C, Suard F, Baumann P, Eap CB, Broly F. Identification of a novel splicesite mutation in the CYP1A2 gene. Br J Clin Pharmacol 2003;56:341--4.10.1046/j.1365-2125.2003.01858.x188434212919186
    Search in Google Scholar
  70. Murayama N, Soyama A, Saito Y, Nakajima Y, Komamura K, Ueno K, Kamakura S, Kitakaze M, Kimura H, Goto Y, Saitoh O, Katoh M, Ohnuma T, Kawai M, Sugai K, Ohtsuki T, Suzuki C, Minami N, Ozawa S, Sawada J. Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J Pharmacol Exp Ther 2004;308:300--6.10.1124/jpet.103.05579814563787
    Search in Google Scholar
  71. Eap CB, Bender S, Jaquenoud Sirot E, Cucchia G, Jonzier-Perey M, Baumann P, Allorge D, Broly F. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol 2004;24:214--9.10.1097/01.jcp.0000116646.91923.2f15206669
    Search in Google Scholar
  72. Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, Eap CB. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 2005;27:539--43.10.1097/01.ftd.0000164609.14808.9316044115
    Search in Google Scholar
  73. Bohanec Grabar P, Rozman B, Tomsic M, Suput D, Logar D, Dolzan V. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol 2008;64:871--6.10.1007/s00228-008-0498-218496682
    Search in Google Scholar
  74. Saebø M, Skjelbred CF, Brekke Li K, Bowitz Lothe IM, Hagen PC, Johnsen E, Tveit KM, Kure EH. CYP1A2 164 A polymorphism, cigarette smoking, consumption of welldone red meat and risk of developing colorectal adenomas and carcinomas. Anticancer Res 2008;28:2289--5.
    Search in Google Scholar
  75. Moonen H, Engels L, Kleinjans J, Kok T. The CYP1A2-164A-->C polymorphism (CYP1A2*1F) is associated with the risk for colorectal adenomas in humans. Cancer Lett 2005;229:25--31.10.1016/j.canlet.2004.12.01016157215
    Search in Google Scholar
  76. Suzuki H, Morris JS, Li Y, Doll MA, Hein DW, Liu J, Jiao L, Hassan MM, Day RS, Bondy ML, Abbruzzese JL, Li D. Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer. Carcinogenesis 2008;29:1184--91.10.1093/carcin/bgn085244327818499698
    Search in Google Scholar
  77. Li D, Jiao L, Li Y, Doll MA, Hein DW, Bondy ML, Evans DB, Wolff RA, Lenzi R, Pisters PW, Abbruzzese JL, Hassan MM. Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis 2006;27:103--11.10.1093/carcin/bgi171135061015987714
    Search in Google Scholar
  78. Pavanello S, B'chir F, Pulliero A, Saguem S, Ben Fraj R, El Aziz Hayouni A, Clonfero E, Mastrangelo G. Interaction between CYP1A2-T2467DELT polymorphism and smoking in adenocarcinoma and squamous cell carcinoma of the lung. Lung Cancer 2007;57:266--72.10.1016/j.lungcan.2007.04.00417509724
    Search in Google Scholar
  79. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47:445--9.10.1046/j.1365-2125.1999.00898.x201423310233211
    Search in Google Scholar
  80. Han XM, Ou-Yang DS, Lu PX, Jiang CH, Shu Y, Chen XP, Tan ZR, Zhou HH. Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics 2001;11:429--35.10.1097/00008571-200107000-0000611470995
    Search in Google Scholar
  81. Castorena-Torres F, Mendoza-Cantú A, de León MB, Cisneros B, Zapata-Pérez O, López-Carrillo L, Salinas JE, Albores A. CYP1A2 phenotype and genotype in a population from the Carboniferous Region of Coahuila, Mexico. Toxicol Lett 2005;156:331--9.10.1016/j.toxlet.2004.12.00515763632
    Search in Google Scholar
  82. Nkondjock A, Ghadirian P, Kotsopoulos J, Lubinski J, Lynch H, Kim-Sing C, Horsman D, Rosen B, Isaacs C, Weber B, Foulkes W, Ainsworth P, Tung N, Eisen A, Friedman E, Eng C, Sun P, Narod SA. Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Cancer 2006;118:103--7.10.1002/ijc.21296
    Search in Google Scholar
  83. Kotsopoulos J, Ghadirian P, El-Sohemy A, Lynch HT, Snyder C, Daly M, Domchek S, Randall S, Karlan B, Zhang P, Zhang S, Sun P, Narod SA. The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers. Cancer Epidemiol Biomarkers Prev 2007;16:912--6.10.1158/1055-9965.EPI-06-1074
    Search in Google Scholar
  84. Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 2006;295:1135--41.10.1001/jama.295.10.1135
    Search in Google Scholar
  85. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP, Sutter TR. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 1996;56:2979--84.
    Search in Google Scholar
  86. Murray GI, Melvin WT, Greenlee WF, Burke MD. Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol 2001;41:297--316.10.1146/annurev.pharmtox.41.1.297
    Search in Google Scholar
  87. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR. 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci USA 1996;93:9776--81.10.1073/pnas.93.18.9776
    Search in Google Scholar
  88. McKay JA, Melvin WT, Ah-See AK, Ewen SW, Greenlee WF, Marcus CB, Burke MD, Murray GI. Expression of cytochrome P450 CYP1B1 in breast cancer. FEBS Lett 1995;374:270--2.10.1016/0014-5793(95)01126-Y
    Search in Google Scholar
  89. Crespi CL, Penman BW, Steimel DT, Smith T, Yang CS, Sutter TR. Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: substrate specificity with model substrates and promutagens. Mutagenesis 1997;12:83--9.10.1093/mutage/12.2.839106248
    Search in Google Scholar
  90. Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD, Melvin WT. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 1997;57:3026--31.
    Search in Google Scholar
  91. Stoilov I, Akarsu AN, Alozie I, Child A, Barsoum-Homsy M, Turacli ME, Or M, Lewis RA, Ozdemir N, Brice G, Aktan SG, Chevrette L, Coca-Prados M, Sarfarazi M. Sequence analysis and homology modelling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet 1998;62:573--84.10.1086/30176413769589497261
    Search in Google Scholar
  92. Van Emburgh BO, Hu JJ, Levine EA, Mosley LJ, Perrier ND, Freimanis RI, Allen GO, Rubin P, Sherrill GB, Shaw CS, Carey LA, Sawyer LR, Miller MS. Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer. Oncol Rep 2008;19:1311--21.10.3892/or.19.5.1311
    Search in Google Scholar
  93. Van Emburgh BO, Hu JJ, Levine EA, Mosley LJ, Case LD, Lin HY, Knight SN, Perrier ND, Rubin P, Sherrill GB, Shaw CS, Carey LA, Sawyer LR, Allen GO, Milikowski C, Willingham MC, Miller MS. Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer. Mol Carcinogen 2008;47:88--99.10.1002/mc.20365372235917683074
    Search in Google Scholar
  94. Justenhoven C, Pierl CB, Haas S, Fischer HP, Baisch C, Hamann U, Harth V, Pesch B, Brüning T, Vollmert C, Illig T, Dippon J, Ko YD, Brauch H. The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer. Breast Cancer Res Treat 2008;111:171--7.10.1007/s10549-007-9762-x17922187
    Search in Google Scholar
  95. Paracchini V, Raimondi S, Gram IT, Kang D, Kocabas NA, Kristensen VN, Li D, Parl FF, Rylander-Rudqvist T, Soucek P, Zheng W, Wedren S, Taioli E. Meta- and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer: a HuGE-GSEC review. Am J Epidemiol 2007;165:115--25.10.1093/aje/kwj36517053044
    Search in Google Scholar
  96. Bethke L, Webb E, Sellick G, Rudd M, Penegar S, Withey L, Qureshi M, Houlston R. Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk. BMC Cancer 2007;7:123.10.1186/1471-2407-7-123192511117615053
    Search in Google Scholar
  97. Singh AP, Shah PP, Mathur N, Buters JT, Pant MC, Parmar D. Genetic polymorphisms in cytochrome P4501B1 and susceptibility to head and neck cancer. Mutat Res 2008;639:11--9.10.1016/j.mrfmmm.2007.10.00718067928
    Search in Google Scholar
  98. Harth V, Schafer M, Abel J, Maintz L, Neuhaus T, Besuden M, Primke R, Wilkesmann A, Thier R, Vetter H, Ko YD, Bruning T, Bolt HM, Ickstadt K. Head and neck squamouscell cancer and its association with polymorphic enzymes of xenobiotic metabolism and repair. J Toxicol Environ Health A 2008;71:887--97.10.1080/1528739080198816018569591
    Search in Google Scholar
  99. Ickstadt K, Schäfer M, Fritsch A, Schwender H, Abel J, Bolt HM, Brüning T, Ko YD, Vetter H, Harth V. Statistical methods for detecting genetic interactions: a head and neck squamous-cell cancer study. J Toxicol Environ Health A 2008;71:803--15.10.1080/1528739080198574518569579
    Search in Google Scholar
  100. Küry S, Buecher B, Robiou-du-Pont S, Scoul C, Sébille V, Colman H, Le Houérou C, Le Neel T, Bourdon J, Faroux R, Ollivry J, Lafraise B, Chupin LD, Bézieau S. Combinations of cytochrome P450 gene polymorphisms enhancing the risk for sporadic colorectal cancer related to red meat consumption. Cancer Epidemiol Biomarkers Prev 2007;16:1460--7.10.1158/1055-9965.EPI-07-023617627011
    Search in Google Scholar
  101. Beuten J, Gelfond JA, Byrne JJ, Balic I, Crandall AC, Johnson-Pais TL, Thompson IM, Price DK, Leach RJ. CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians. Carcinogenesis 2008;29:1751--7.10.1093/carcin/bgm300252764718544568
    Search in Google Scholar
  102. Sissung TM, Danesi R, Price DK, Steinberg SM, de Wit R, Zahid M, Gaikwad N, Cavalieri E, Dahut WL, Sackett DL, Figg WD, Sparreboom A. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther 2008;7:19--26.10.1158/1535-7163.MCT-07-055718187806
    Search in Google Scholar
  103. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45:525--38.10.1046/j.1365-2125.1998.00721.x18736509663807
    Search in Google Scholar
  104. Goldstein JA. Clinical relevance of genetic polymorphism in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52:349--55.10.1046/j.0306-5251.2001.01499.x
    Search in Google Scholar
  105. Yao HT, Chang YW, Lan SJ, Chen CT, Hsu JT, Yeh TK. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci 2006;79:2432--40.10.1016/j.lfs.2006.08.016
    Search in Google Scholar
  106. Yun CH, Shimada T, Guengerich FP. Roles of human liver cytochrome P4502C and 3A enzymes in the 3-hydroxylation of benzo(a)pyrene. Cancer Res 1992;52:1868--74.
    Search in Google Scholar
  107. Yamazaki H, Inoue K, Chiba K, Ozawa N, Kawai T, Suzuki Y, Goldstein JA, Guengerich FP, Shimada T. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol 1998;56:243--51.10.1016/S0006-2952(98)00133-6
    Search in Google Scholar
  108. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002;12:251--63.10.1097/00008571-200204000-0001011927841
    Search in Google Scholar
  109. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996;333:447--58.10.1006/abbi.1996.04148809086
    Search in Google Scholar
  110. Yin T, Maekawa K, Kamide K, Saito Y, Hanada H, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, Otsuki T, Horio T, Takiuchi S, Kawano Y, Minematsu K, Naritomi H, Tomoike H, Sawada J, Miyata T. Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res 2008;31:1549--57.10.1291/hypres.31.154918971529
    Search in Google Scholar
  111. Brandolese R, Scordo MG, Spina E, Gusella M, Padrini R. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin Pharmacol Ther 2001;70:391--4.10.1067/mcp.2001.118868
    Search in Google Scholar
  112. Sconce EA, Khan TI, Wynne AH, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005;106:2329--33.10.1182/blood-2005-03-110815947090
    Search in Google Scholar
  113. Redman AR, Zheng J, Shamsi SA, Huo J, Kelly EJ, Ho RJY, Ritchie DM, Hon YY. Variant CYP2C9 alleles and warfarin concentrations in patients receiving low-dose versus average-dose warfarin therapy. Clin Appl Thromb Haemost 2008;14:29--37.10.1177/107602960730440317895500
    Search in Google Scholar
  114. Rollason V, Samer C, Piguet V, Dayer P, Desmeules J. Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics 2008;9:905--33.10.2217/14622416.9.7.90518597654
    Search in Google Scholar
  115. Cross JT, Poole EM, Ulrich CM. A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia. Pharmacogenomics J 2008;8:237--47.10.1038/sj.tpj.6500487260357618195728
    Search in Google Scholar
  116. Samowitz WS, Wolff RK, Curtin K, Sweeney C, Ma KN, Andersen K, Levin TR, Slattery ML. Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Clin Gastroenterol Hepatol 2006;4:894--901.10.1016/j.cgh.2006.04.02116797247
    Search in Google Scholar
  117. Zandvliet AS, Huitema AD, Copalu W, Yamada Y, Tamura T, Beijnen JH, Schellens JH. CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity. Clin Cancer Res 2007;13:2970--6.10.1158/1078-0432.CCR-06-297817504998
    Search in Google Scholar
  118. Sandberg M, Johansson I, Christensen M, Rane A, Eliasson E. The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype. Drug Metab Dispos 2004;32:484--9.10.1124/dmd.32.5.48415100169
    Search in Google Scholar
  119. García-Martín E, Martínez C, Ladero JM, Agúndez JA. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 2006;10:29--40.10.1007/BF0325644016646575
    Search in Google Scholar
  120. Goldstein JA, Ishizaki T, Chiba K, de Morais SMF, Bell D, Krahn PM, Price Evans DA. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997;7:59--64.10.1097/00008571-199702000-000089110363
    Search in Google Scholar
  121. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Pharmacol Toxicol 2004;95:2--8.10.1111/j.1600-0773.2004.pto950102.x15245569
    Search in Google Scholar
  122. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002;41:913--58.10.2165/00003088-200241120-0000212222994
    Search in Google Scholar
  123. Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 2008;83:322--7.10.1038/sj.clpt.610029117625515
    Search in Google Scholar
  124. Hirt D, Mentré F, Tran A, Rey E, Auleley S, Salmon D, Duval X, Tréluyer JM; COPHAR2- ANRS Study Group. Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients. Br J Clin Pharmacol 2008;65:548--57.10.1111/j.1365-2125.2007.03039.x229139017922881
    Search in Google Scholar
  125. Elmaagacli AH, Koldehoff M, Steckel NK, Trenschel R, Ottinger H, Beelen DW. Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation. Bone Marrow Transplant 2007;40:659--64.10.1038/sj.bmt.1705786
    Search in Google Scholar
  126. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006;57:119--37.10.1146/annurev.med.56.082103.104724
    Search in Google Scholar
  127. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002;34:83--448.10.1081/DMR-120001392
    Search in Google Scholar
  128. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. http://medicine.iupui.edu/flockhart/table.htm
    Search in Google Scholar
  129. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002;53:111--22.10.1046/j.0306-5251.2001.01548.x
    Search in Google Scholar
  130. Hiroi T, Imaoka S, Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 1988;249:838--43.10.1006/bbrc.1998.9232
    Search in Google Scholar
  131. Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F, Tong Y, Carrier DJ, Cheboyina S, Battu SK. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res 2008;52:755--63.10.1002/mnfr.200600300
    Search in Google Scholar
  132. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenom J 2005;5:6--13.10.1038/sj.tpj.6500285
    Search in Google Scholar
  133. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000;356:1667--71.10.1016/S0140-6736(00)03167-6
    Search in Google Scholar
  134. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997;37:269--96.10.1146/annurev.pharmtox.37.1.2699131254
    Search in Google Scholar
  135. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996;278:441--6.
    Search in Google Scholar
  136. Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ, Meyer UA, Broly F. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997;7:193--202.10.1097/00008571-199706000-000049241659
    Search in Google Scholar
  137. Scordo MG, Caputi AP, D'Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004;50:195--200.10.1016/j.phrs.2004.01.00415177309
    Search in Google Scholar
  138. Tamminga WJ, Wemer J, Oosterhuis B, de Zeeuw RA, de Leij LF, Jonkman JH. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur J Clin Pharmacol 2001;57:717--22.10.1007/s00228010035911829201
    Search in Google Scholar
  139. Božina N, Granić P, Lalić Z, Tramišak I, Lovrić M, Stavljenić-Rukavina A. Genetic Polymorphisms of Cytochromes P450: CYP2C9, CYP2C19 and CYP2D6 in Croatian Population. Croat Med J 2003;44:425--8.
    Search in Google Scholar
  140. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007;17:93--101.10.1097/01.fpc.0000239974.69464.f217301689
    Search in Google Scholar
  141. Frank D, Jaehde U, Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 2007;63:321--33.10.1007/s00228-006-0250-817273835
    Search in Google Scholar
  142. Božina N, Tramišak I, Medved V, Mihaljević-Peleš A, Granić P, Stavljenić-Rukavina A. CYP2D6 genotype and psychotropic drug-induced adverse effects. Period biol 2001;103:309--14.
    Search in Google Scholar
  143. Wuttke H, Rau T, Heide R, Bergmann K, Böhm M, Weil J, Werner D, Eschenhagen T. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002;72:429--37.10.1067/mcp.2002.12711112386645
    Search in Google Scholar
  144. Lam YW, Gaedigk A, Ereshefsky L, Alfaro CL, Simpson J. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 2002;22:1001--6.10.1592/phco.22.12.1001.3360312173784
    Search in Google Scholar
  145. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmöller J. Pharmacogenetic of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004;9:442--73.10.1038/sj.mp.400149415037866
    Search in Google Scholar
  146. Preskorn SH, Greenblatt DJ, Flockhart D, Luo Y, Perloff ES, Harmatz JS, Baker B, Klick-Davis A, Desta Z, Burt T. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol 2007;27:28--34.10.1097/00004714-200702000-0000517224709
    Search in Google Scholar
  147. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758--64.10.1093/jnci/djg10814652237
    Search in Google Scholar
  148. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. New Engl J Med 2004;351:2827--31.10.1056/NEJMoa04188815625333
    Search in Google Scholar
  149. Madadi P, Ross CJ, Hayden MR, Carleton BC, Gaedigk A, Leeder JS, Koren G. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther 2009;85:31--5.10.1038/clpt.2008.15718719619
    Search in Google Scholar
  150. Shen H, He MM, Liu H, Wrighton SA, Wang L, Guo B, Li C. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab Dispos 2007;35:1292--300.10.1124/dmd.107.01535417470523
    Search in Google Scholar
  151. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzales FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000;105:1067--75.10.1172/JCI881430083310772651
    Search in Google Scholar
  152. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, Beaune P, Guillouzo A. Cytokines down-regulate expression of major cytochrome P-450 enzyme in adult human hepatocytes in primary culture. Mol Pharmacol 1993;44:707--15.
    Search in Google Scholar
  153. Kessova I, Cederbaum AI. CYP2E1: biochemistry, toxicology, regulation and function in ethanol-induced liver injury. Curr Mol Med 2003;3:509--18.10.2174/156652403347960914527082
    Search in Google Scholar
  154. Villeneuve JP, Pichette V. Cytochrome P450 and liver diseases. Curr Drug Metab 2004;5:273--82.10.2174/138920004333553115180496
    Search in Google Scholar
  155. Bolt HM, Roos PH, Thier R. The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine. Int Arch Occup Environ Health 2003;76:174--85.10.1007/s00420-002-0407-412690492
    Search in Google Scholar
  156. Yin H, Anders MW, Korzekwa KR, Higgins L, Thummel KE, Kharasch ED, Jones JP. Designing safer chemicals: predicting the rates of metabolism of halogenated alkanes. Proc Natl Acad Sci USA 1995;92:11076--80.10.1073/pnas.92.24.11076405747479940
    Search in Google Scholar
  157. Gao CM, Takezaki T, Wu JZ, Chen MB, Liu YT, Ding JH, Sugimura H, Cao J, Hamajima N, Tajima K. CYP2E1 Rsa I polymorphism impacts on risk of colorectal cancer association with smoking and alcohol drinking. World J Gastroenterol 2007;13:5725--30.10.3748/wjg.v13.i43.5725417125817963298
    Search in Google Scholar
  158. Schindler J, Li Y, Marion MJ, Paroly A, Brandt-Rauf PW. The effect of genetic polymorphisms in the vinyl chloride metabolic pathway on mutagenic risk. J Hum Genet 2007;52:448--55.10.1007/s10038-007-0134-517384900
    Search in Google Scholar
  159. Hsieh HI, Chen PC, Wong RH, Wang JD, Yang PM, Cheng TJ. Effect of the CYP2E1 genotype on vinyl chloride monomer-induced liver fibrosis among polyvinyl chloride workers. Toxicology 2007;239:34--44.10.1016/j.tox.2007.06.08917659824
    Search in Google Scholar
  160. Zhu SM, Xia ZL, Wang AH, Ren XF, Jiao J, Zhao NQ, Qian J, Jin L, Christiani DC. Polymorphisms and haplotypes of DNA repair and xenobiotic metabolism genes and risk of DNA damage in Chinese vinyl chloride monomer (VCM)-exposed workers. Toxicol Lett 2008;178:88--94.10.1016/j.toxlet.2008.02.009
    Search in Google Scholar
  161. Arif E, Vibhuti A, Alam P, Deepak D, Singh B, Athar M, Pasha MA. Association of CYP2E1 and NAT2 gene polymorphisms with chronic obstructive pulmonary disease. Clin Chim Acta 2007;382:37--42.10.1016/j.cca.2007.03.013
    Search in Google Scholar
  162. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland LB, Canzian F, Haugen A. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis 2008;29:1164--9.10.1093/carcin/bgn020
    Search in Google Scholar
  163. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008;9:310--22.10.2174/138920008784220664
    Search in Google Scholar
  164. Kapelyukh Y, Paine MJ, Maréchal JD, Sutcliffe MJ, Wolf CR, Roberts GC. Multiple substrate binding by cytochrome P450 3A4: estimation of the number of bound substrate molecules. Drug Metab Dispos 2008;36:2136--44.10.1124/dmd.108.021733
    Search in Google Scholar
  165. Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, Watkins PB. The human CYP3A subfamily: practical considerations. Drug Metab Rev 2000;32:339--61.10.1081/DMR-100102338
    Search in Google Scholar
  166. Kamdem LK, Meineke I, Gödtel-Armbrust U, Brockmöller J, Wojnowski L. Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1. Chem Res Toxicol 2006;19:577--86.10.1021/tx050358e
    Search in Google Scholar
  167. Kale VM, Miranda SR, Wilbanks MS, Meyer SA. Comparative cytotoxicity of alachlor, acetochlor, and metolachlor herbicides in isolated rat and cryopreserved human hepatocytes. J Biochem Mol Toxicol 2008;22:41--50.10.1002/jbt.20213
    Search in Google Scholar
  168. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1--17.10.1146/annurev.pharmtox.39.1.1
    Search in Google Scholar
  169. Finta C, Zaphiropoulos PG. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 2000;260:13--23.10.1016/S0378-1119(00)00470-4
    Search in Google Scholar
  170. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. Expression of CYP3A in the human liver: evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997;247:625--34.10.1111/j.1432-1033.1997.00625.x9266706
    Search in Google Scholar
  171. Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, Tandler PJ, Zaya MJ. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 2003;307:573--82.10.1124/jpet.103.05484112975492
    Search in Google Scholar
  172. Rodríguez-Antona C, Jande M, Rane A, Ingelman-Sundberg M. Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers. Clin Pharmacol Ther 2005;77:259--70.10.1016/j.clpt.2004.11.00315903124
    Search in Google Scholar
  173. Buratti FM, Leoni C, Testai E. Foetal and adult human CYP3A isoforms in the bioactivation of organophosphorothionate insecticides. Toxicol Lett 2006;167:245--55.10.1016/j.toxlet.2006.10.00617110060
    Search in Google Scholar
  174. Nivoix Y, Levêque D, Herbrecht R, Koffel JC, Beretz L, Ubeaud-Sequier G. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 2008;47:779--92.10.2165/0003088-200847120-0000319026034
    Search in Google Scholar
  175. Zhang X, Jones DR, Hall SD. Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition. Drug Metab Dispos 2009;37:150--60.10.1124/dmd.108.02217818854379
    Search in Google Scholar
  176. Kapelyukh Y, Paine MJ, Maréchal JD, Sutcliffe MJ, Wolf CR, Roberts GC. Multiple substrate binding by cytochrome P450 3A4: estimation of the number of bound substrate molecules. Drug Metab Dispos 2008;36:2136--44.10.1124/dmd.108.02173318645035
    Search in Google Scholar
  177. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, Kliewer SA. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000;97:7500--2.10.1073/pnas.1301550971657410852961
    Search in Google Scholar
  178. Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 2008;47:463--74.10.2165/00003088-200847070-0000318563955
    Search in Google Scholar
  179. Ohno Y, Hisaka A, Ueno M, Suzuki H. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet 2008;47:669--80.10.2165/00003088-200847100-0000418783297
    Search in Google Scholar
  180. Spigset O, Molden E. Cytokrom P-450 3A4 - kroppens viktigste arena for legemiddelinteraksjoner Tidsskr Nor Laegeforen 2008;128:2832--5.
    Search in Google Scholar
  181. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5-upstream regulatory region. Biochem Biophys Res Commun 1999;259:201--5.10.1006/bbrc.1999.0752
    Search in Google Scholar
  182. Canaparo R, Finnström N, Serpe L, Nordmark A, Muntoni E, Eandi M, Rane A, Zara GP. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clin Exp Pharmacol Physiol 2007;34:1138--44.10.1111/j.1440-1681.2007.04691.x
    Search in Google Scholar
  183. From MF. Genetically determined differences in Pglycoprotein function, implications for disease risk. Toxicology 2002;181-182:299--303.10.1016/S0300-483X(02)00297-4
    Search in Google Scholar
  184. Ieiri I, Hiroshi T, Otsubo K. The MDR1(ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 2004;43:553--76.10.2165/00003088-200443090-00001
    Search in Google Scholar
  185. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001;276:14581--7.10.1074/jbc.M010173200
    Search in Google Scholar
  186. Olinga P, Elferink MG, Draaisma AL, Merema MT, Castell JV, Pérez G, Groothuis GM. Coordinated induction of drug transporters and phase I and II metabolism in human liver slices. Eur J Pharm Sci 2008;33:380--9.10.1016/j.ejps.2008.01.008
    Search in Google Scholar
  187. Watkins PB. The barrier function of CYP3A4 and Pglycoprotein in the small bowel. Adv Drug Deliv Rev 1997;27:161--70.10.1016/S0169-409X(97)00041-0
    Search in Google Scholar
  188. Hesselink DA. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003;74:245--54.10.1016/S0009-9236(03)00168-1
    Search in Google Scholar
  189. von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivistö KT. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004;75:172--83.10.1016/j.clpt.2003.10.00815001968
    Search in Google Scholar
  190. van Waterschoot RA, Rooswinkel RW, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Schinkel AH. Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver. FASEB J 2009;23:224--31.10.1096/fj.08-11487618794335
    Search in Google Scholar
  191. Rodríguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun 2005;338:299--305.10.1016/j.bbrc.2005.09.02016171783
    Search in Google Scholar
  192. Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol 2007;47:566--78.10.1177/009127000729993017442683
    Search in Google Scholar
  193. Lamba J, Lamba V, Schuetz E. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 2005;6:369--83.10.2174/138920005463388016101575
    Search in Google Scholar
  194. Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, Fuss C, Brehm I, Brinkmann U, Eichelbaum M, Wojnowski L, Burk O. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 2001;29:1454--9.
    Search in Google Scholar
  195. Rodríguez-Antona C, Jande M, Rane A, Ingelman-Sundberg M. Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers. Clin Pharmacol Ther 2005;77:259--70.10.1016/j.clpt.2004.11.00315903124
    Search in Google Scholar
  196. Leeder JS, Gaedigk R, Marcucci KA, Gaedigk A, Vyhlidal CA, Schindel BP, Pearce RE. Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther 2005;314:626--35.10.1124/jpet.105.08650415845858
    Search in Google Scholar
  197. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383--91.10.1038/8688211279519
    Search in Google Scholar
  198. Roberts PJ, Rollins KD, Kashuba AD, Paine MF, Nelsen AC, Williams EE, Moran C, Lamba JK, Schuetz EG, Hawke RL. The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans. Drug Metab Dispos 2008;36:1465--9.10.1124/dmd.107.020065277034518490434
    Search in Google Scholar
  199. Daly AK. Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 2006;45:13--31.10.2165/00003088-200645010-0000216430309
    Search in Google Scholar
  200. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmöller J, Halpert JR, Zanger UM, Wojnowski L. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11:773--9.10.1097/00008571-200112000-0000511740341
    Search in Google Scholar
  201. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002;62:162--72.10.1124/mol.62.1.16212065767
    Search in Google Scholar
  202. Anglicheau D, Legendre C, Beaune P, Thervet E. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics 2007;8:835--49.10.2217/14622416.8.7.83518240909
    Search in Google Scholar
  203. Crettol S, Venetz JP, Fontana M, Aubert JD, Pascual M, Eap CB. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit 2008;30:689--99.10.1097/FTD.0b013e31818a2a6018978522
    Search in Google Scholar
  204. Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 2007;22:328--35.10.2133/dmpk.22.32817965516
    Search in Google Scholar
  205. Keshava C, McCanlies EC, Weston A. CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol 2004;160:825--41.10.1093/aje/kwh29415496535
    Search in Google Scholar
  206. Vaarala MH, Mattila H, Ohtonen P, Tammela TL, Paavonen TK, Schleutker J. The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer. Int J Cancer 2008;122:2511--6.10.1002/ijc.2342518306354
    Search in Google Scholar
  207. Plummer SJ, Conti DV, Paris PL, Curran AP, Casey G, Witte JS. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003;12:928--32.
    Search in Google Scholar
  208. Bangsi D, Zhou J, Sun Y, Patel NP, Darga LL, Heilbrun LK, Powell IJ, Severson RK, Everson RB. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men. Urol Oncol 2006;24:21--7.10.1016/j.urolonc.2005.09.00516414488
    Search in Google Scholar
  209. Jin M, Gock SB, Jannetto PJ, Jentzen JM, Wong SH. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J Anal Toxicol 2005;29:590--8.10.1093/jat/29.7.59016419387
    Search in Google Scholar
  210. U.S. Food and Drug Administration (FDA). Genomics at FDA. Available at http://www.fda.gov/cder/genomics
    Search in Google Scholar
  211. de Leon J, Susce MT, Murray-Carmichael E. The AmpliChipCYP450 genotyping test: intergrating a new clinical tool. Mol Diagn Ther 2006;10:135--51.10.1007/BF0325645316771600
    Search in Google Scholar
  212. Mendrick DL. Translational medicine: the discovery of bridging biomarkers using pharmacogenomics. Pharmacogenomics 2006;7:943--7.10.2217/14622416.7.6.94316981852
    Search in Google Scholar
DOI: https://doi.org/10.2478/10004-1254-60-2009-1885 | Journal eISSN: 1848-6312 | Journal ISSN: 0004-1254
Journal RSS Feed
Language: English, Croatian, Slovenian
Page range: 217 - 242
Published on: Jul 6, 2009
Published by: Institute for Medical Research and Occupational Health
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
cancer risk,
cytochrome P450,
drug metabolism,
genotyping,
pharmacogenomics,
polymorphic allele,
xenobiotics
Related subjects:
Medicine,
Basic medical science,
Basic medical science, other

© 2009 Nada Božina, Vlasta Bradamante, Mila Lovrić, published by Institute for Medical Research and Occupational Health
This work is licensed under the Creative Commons License.

Volume 60 (2009): Issue 2 (June 2009)